Monday, February 7, 2011
pSivida Corp., of Watertown, Mass., and Alimera Sciences Inc., of Atlanta, reported 36-month, top-line results for the FAME study of Iluvien in diabetic macular edema, showing statistically significant therapeutic effects with 28.9 percent at month 30 (p = 0.011) and 28.4 percent at month 33 (p = 0.042) of Iluvien patients gaining 15 or more letters compared to the control group, in which fewer than 17 percent of patients gained 15 or more letters.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.